Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$82.77-5.10%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Tarsus aims to grow XDEMVY sales to $670-700M in 2026. Revenue rose from $151.7M in 2025-Q4 to $162.1M in 2026-Q1. The company expanded its board to strengthen leadership. Analysts expect 42% revenue growth next year.
Tarsus remains loss-making with a net loss of $6.97M in 2026-Q1. The company has missed earnings multiple times recently. Revenue growth may slow and profitability is uncertain.
The stock trades about 55% below our fair value near $152. The market expects about 42% revenue growth. Our view aligns with this but remains cautious on profitability.
Breaks if: Board fails to add value or experiences turnover
Breaks if: Net loss persists or worsens beyond FY27
Revenue falls below $670M in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a speculative growth investment with a focus on expanding product sales and advancing clinical trials. The current thesis state has weakened due to recent financial performance and an earnings miss.
The market seems to price in a low expectations gap, suggesting that TARS is seen as cheap compared to its peers. However, the valuation reflects a premium, indicating some uncertainty about future performance.
Management is on track with priorities like growing net product sales and advancing their pipeline. However, recent financial performance has been weak, and there is a moderate risk of missing future earnings expectations.
The thesis hinges on TARS maintaining credibility by not cutting guidance after a recent raise, as well as the broader healthcare sector's performance. Additionally, the impact of macroeconomic factors, like job reports, could affect TARS more than other companies.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The reason to own TARS has diminished due to recent financial performance. It fell from the robust 68th to the 17th percentile of its sector. Additionally, the company missed earnings expectations, which raises concerns about its future performance. However, there was an increase in full-year 2026 net product sales guidance, which offers some support.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
In the next 1 to 3 years, TARS will need to navigate its growth initiatives while managing recent performance challenges. Not investment advice.